Dr. Raajit K Rampal, MD, PhD
Claim this profileMemorial Sloan Kettering Cancer Center
Studies Myelofibrosis
Studies Uterine Tumors
7 reported clinical trials
10 drugs studied
Area of expertise
1Myelofibrosis
IDH2
2Uterine Tumors
CD123 positive
IDH2
Affiliated Hospitals
Clinical Trials Raajit K Rampal, MD, PhD is currently running
Ruxolitinib + Abemaciclib
for Myelofibrosis
This trial is testing if using two drugs, ruxolitinib and abemaciclib, together can help treat a specific type of blood cancer. The target group is people with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. The drugs work by blocking proteins that cancer cells need to grow and divide. Ruxolitinib is a targeted drug approved for the treatment of myelofibrosis.
Recruiting1 award Phase 1
Avapritinib + Decitabine
for Systemic Mastocytosis
Systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) is a challenging disease to treat. Targeted KIT inhibitors have been approved for this indication based on their ability to control the mastocytosis portion of the disease, but patients frequently experience progression of the concomitant myeloid malignancy (i.e. the AHN). Using a combination approach to treat both aspects of the disease has the potential to provide enhanced disease control; however, overlapping toxicity is a concern. In this study, investigators aim to study the safety and tolerability of combined avapritinib and decitabine for the treatment of SM-AHN.
Recruiting1 award Phase 1
More about Raajit K Rampal, MD, PhD
Clinical Trial Related8 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Raajit K Rampal, MD, PhD has experience with
- Ruxolitinib
- Thalidomide
- IMGN632
- ZN-c3
- ZN-d5
- Pelabresib (CPI-0610)
Breakdown of trials Raajit K Rampal, MD, PhD has run
Myelofibrosis
Uterine Tumors
Myeloproliferative Disorders
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Raajit K Rampal, MD, PhD specialize in?
Raajit K Rampal, MD, PhD focuses on Myelofibrosis and Uterine Tumors. In particular, much of their work with Myelofibrosis has involved IDH2 patients, or patients who are undergoing treatment.
Is Raajit K Rampal, MD, PhD currently recruiting for clinical trials?
Yes, Raajit K Rampal, MD, PhD is currently recruiting for 2 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Raajit K Rampal, MD, PhD has studied deeply?
Yes, Raajit K Rampal, MD, PhD has studied treatments such as Ruxolitinib, Thalidomide, IMGN632.
What is the best way to schedule an appointment with Raajit K Rampal, MD, PhD?
Apply for one of the trials that Raajit K Rampal, MD, PhD is conducting.
What is the office address of Raajit K Rampal, MD, PhD?
The office of Raajit K Rampal, MD, PhD is located at: Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States. This is the address for their practice at the Memorial Sloan Kettering Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.